Non Squamous Non Small Cell Lung Clinical Trial
Official title:
Multicentre, Randomised, Double-blind, Phase III Trial to Investigate the Efficacy and Safety of Oral SHR1020 Plus Docetaxel Therapy Compared to Placebo Plus Docetaxel Therapy in Patients With Local Advanced or Metastatic or Recurrent Non Squamous Non Small Cell Lung Cancer After Failure of First Line Chemotherapy.
| Verified date | December 2018 |
| Source | Jiangsu HengRui Medicine Co., Ltd. |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
The present trial will be performed to evaluate whether SHR1020 in combination with docetaxel in patients with Local Advanced or Metastatic or recurrent Non Squamous NSCLC is more effective as compared to placebo in combination with docetaxel. A secondary aim is to obtain safety information as well as information on quality of life of patients treated with SHR1020 in combination with docetaxel.
| Status | Terminated |
| Enrollment | 12 |
| Est. completion date | November 2016 |
| Est. primary completion date | November 2016 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years to 70 Years |
| Eligibility |
Inclusion Criteria: 1. age:18-70 years 2. Histologically or cytologically confirmed locally advanced and/or metastatic NSCLC or recurrent NSCLC (=9 months from date of diagnosis to randomized ), epidermal growth factor receptor-wild type, Anaplastic Lymphoma Kinase-wild type or unknown mutation 3. At least one lesion that can be accurately measured and has not been received local treatments such as radiotherapy and cryotherapy 4. Relapse or failure of one first line prior platinum-based chemotherapy 5. Eastern Cooperative Oncology Group performance status 0 or 1 6. Life expectancy of at least 12 weeks 7. Adequate organ and bone marrow function as defined below(no blood transfusion or drugs for leucopenia and Platelet within 14 days before screening): (1) HB=90g/l (2) ANC=1.5×10^9/l (3) PLT=100×10^9/l (4) BIL<1.25×upper limit of normal (5) Alanine Aminotransferase and/or AST<2.5×upper limit of normal (< 5×upper limit of normal for patients with liver metastasis) (6) Cr=1.25×upper limit of normal or Creatinine clearance rate>45ml/min ( Cockcroft-Gault Formula) (7) Cholesterol=1.5×upper limit of normal, Triglyceride=2.5×upper limit of normal (8) Left ventricular ejection fraction (LVEF) greater than lower limit of normal 8. Female: child bearing potential, a negative urine or serum pregnancy test result within 7 days before randomisation, agree to use effective contraception while on treatment and for at least 6 months after end of treatment;male: agree to use effective contraception while on treatment and for at least 6 months after end of treatment 9. Patient has given written informed consent Exclusion Criteria: 1. More than one prior chemotherapy regimen for advanced and/or metastatic or recurrent NSCLC (except neoadjuvant or adjuvant chemotherapy ) 2. Previous therapy with other VEGFR inhibitors?recombinant human endostatin? docetaxel or immunotherapy for treatment of NSCLC 3. History of severe hypersensitivity reactions to docetaxel or other drugs formulated with polysorbate 80 (Tween 80), Hypersensitivity to the excipients of the trial drugs or contrast medium 4. Have clinically significant cavity effusion,such as pleural effusion? pericardial effusion or ascites and require clinical intervention 5. Active brain metastases 6. Other malignancy within the past (including primary brain tumor or Leptomeningeal tumor), other than basal cell skin cancer or carcinoma in situ of the cervix 7. Significant weight loss (>10%) within the past 6 weeks 8. Persistence of clinically relevant therapy related toxicities from previous therapy (greater than Common Terminology Criteria for Adverse Event(CTCAE) 4.0 grade 1) 9. Treatment with surgery, chemotherapy, hormone therapy, radiotherapy, immunomodulation or monoclonal antibody therapy within the past 4 weeks and traditional chinese medicine for antitumor therapy within the past 2 weeks before start of therapy 10. Radiographical evidence of cavitary or necrotic tumours 11. Centrally located tumours with radiographical evidence (CT or MRI) of local invasion of major blood vessels 12. Greater than CTCAE 4.0 grade 2 pulmonary hemorrhage within the past one month before screening 13. History of clinically significant haemoptysis within the past 3 months (more than half a teaspoon within 24 hours ) 14. History of major thrombotic or clinically relevant major bleeding event in the past 6 months 15. Prothrombin time (PT) and/or partial thromboplastin time (PTT) > 50% of devi - ation of upper limit of normal 16. Application of anticoagulants or vitamin K antagonists such as warfarin, heparin or its analogus, if INR=1.5, with the purpose of prevention,the use of low-dose warfarin (1mg, qd) or aspirin ( = 100 mg per day ) is allowed 17. Incomplete wound healing or fracture for long time 18. Uncontrolled hypertensin with one antihypertensive agent, unstable angina, history of myocardial infarction in the past 6 months, congestive heart failure>NYHA II, serious cardiac arrhythmia 19. Urinary protein=++ and confirmed 24-hour urinary protein greater than 1.0g; 20. Preexisting thyroid dysfunction, even with medical therapy, thyroid function can not be maintained in the normal range 21. Uncontrolled diabetes mellitus with antidiabetic therapy 22. Current peripheral neuropathy greater than CTCAE 4.0 grade 2 23. Active or chronic hepatitis C and/or B infection with liver dysfunction 24. History of immunodeficiency diseases, other acquired or congenital immunodeficiency diseases, or history of organ transplantation 25. Serious infections requiring systemic antibiotic therapy 26. Variety of factors that affect the oral medication (such as unable to swallow, chronic diarrhea, bowel obstruction and other gastrointestinal disorders or abnormalities 27. Pregnancy or breast feeding 28. Active alcohol or drug abuse 29. Treatment in another clinical trial within the past 4 weeks before start of therapy 30. Psychological, familial, sociological, or geographical factors potentially hampering compliance with the study protocol and follow-up schedule 31. According to the investigator, other conditions that may increase the risk associated with patient safety and study participation |
| Country | Name | City | State |
|---|---|---|---|
| China | Shanghai Pulmonary Hospital | Shanghai | Shanghai |
| Lead Sponsor | Collaborator |
|---|---|
| Jiangsu HengRui Medicine Co., Ltd. | Shanghai Pulmonary Hospital, Shanghai, China |
China,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Overall Survival | approximately 30 months | ||
| Secondary | Progression Free Survival (PFS) | approximately 30 months | ||
| Secondary | Incidence and Intensity of Adverse Events | From signing informed consent document until 30 days after the last drug administration | ||
| Secondary | Objective Tumour Response (Complete Response Plus Partial Response) Using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 | approximately 30months | ||
| Secondary | Disease Control (Complete Response Plus Partial Response plus stable disease) Using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 | approximately 30months | ||
| Secondary | Quality of Life (QoL) measured by standardised questionnaires (EORTC Quality of Life Questionnaire-C30) | approximately 30months |